Company coronavirus news summary – Moderna and Israel expands Covid-19 vaccine supply agreement – India grants emergency approval to Pfizer’s Covid-19 vaccine

7 December 2020 (Last Updated December 7th, 2020 08:26)

7 December 2020 

Moderna announced that it has expanded its supply agreement with the Ministry of Health of Israel by an additional four million doses of the mRNA-1273 vaccine for Covid-19. While the Ministry of Health in Israel is yet to complete regulatory approval for the vaccine, the country has secured access to six million doses of mRNA-1273 through the expanded agreement.

Clover Biopharmaceuticals announced positive clinical results from its Phase I trial . The results demonstrated that Clover’s protein-based Covid-19 S-Trimer vaccine candidates with GlaxoSmithKline or Dynavax adjuvants induced strong immune responses, including neutralising antibodies and cell-mediated immunity. The vaccines were also found to be safe and tolerable among 150 adults and elderly volunteers.

Eli Lilly and UnitedHealth Group are collaborating to study bamlanivimab (LY-CoV555) in high-risk, Covid-19 individuals in areas such as symptom tracking, in-home testing and in-home infusions to detect the SAR-CoV-2 virus. Bamlanivimab was recently granted emergency use authorisation by the US Food and Drug Administration (FDA) for treating mild to moderate Covid-19 patients who were at high risk of developing severe Covid-19 and/or hospitalisation.

The Drugs Controller General of India (DCGI) granted emergency use authorisation to Pfizer India for its Covid-19 vaccine, making it the first company to get the approval in the country and after its parent company secured clearance in the UK and Bahrain. Officials reported that the company has sought permission from the drug regulator to import the vaccine for sale and distribution in the country.